Iwona Baranowska

Abstract Chronic lymphocytic leukemia (CLL) represents the most common form of adult B-cell malignancy. Although significant therapeutic progress has been made in the recent years, novel molecular targets are still being investigated, and the management of relapsed or refractory (r/r) CLL remains challenging. Chimeric antigen receptor (CAR)-T cell therapies have revolutionized treatment in other B-cell malignancies and are emerging as a feasible option for a subset of r/r CLL patients.

Abstract Immunotherapy revolutionized cancer treatment in the last decade. Natural killer (NK) cells are one of the key host immunity components against malignant cells. Thus, they are currently extensively investigated in the field of immunotherapy of cancer. Different approaches have been developed to improve the antitumor activity of NK cells. Nonetheless, tumor microenvironment remains an obstacle to effective NK cell-based therapies.

Abstract Development of efficient vectors for transfection is one of the major challenges in genetic engineering. Previous research demonstrated that cationic derivatives of polyisoprenoids (PTAI) may serve as carriers of nucleic acids. In the present study, the effectiveness of two PTAI-based formulations (PTAI-6–8 and 10–14) was investigated and compared to the commercial reagents.